A pipeline of new possibilities

Our current pipeline

We are on the cutting edge of uro-oncology with the development of our investigational product candidates, which we believe have the potential to upend the status quo and open up new avenues to treat patients.

Uro-oncology

UGN-102

Low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC)

Nonclinical

Phase 1

Phase 2

Phase 3

Registration

Uro-oncology

UGN-103

Low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC)

Nonclinical

Phase 1

Phase 2

Phase 3

Starting
in 2024

Registration

Uro-oncology

UGN-104

Low-grade upper tract urothelial cancer (UTUC)

Nonclinical

Phase 1

Phase 2

Phase 3

Estimated
Early 2025

Registration

immuno-Uro-oncology

UGN-301

(Anti-CTLA-4)

High-grade non-muscle invasive bladder cancer (NMIBC)

Nonclinical

Phase 1

Phase 2

Phase 3

Registration

immuno-Uro-oncology

UGN-301 + UGN-201

(TLR 7 agonist)

High-grade non-muscle invasive bladder cancer (NMIBC)

Nonclinical

Phase 1

Phase 2

Phase 3

Registration

immuno-Uro-oncology

UGN-301 + gemcitabine

High-grade non-muscle invasive bladder cancer (NMIBC)

Nonclinical

Phase 1

Phase 2

Phase 3

Registration

UGN-102, UGN-103, UGN-104, UGN-301, and UGN-201 are investigational drugs in development. The safety and efficacy of these agents have not been established by any regulatory body including the FDA.

We are always exploring new ways to utilize RTGel® technology to bring more possibilities to patients. If you are interested in a potential partnership with UroGen, please contact Timothy Simon in Business Development.

Our story
of bringing possibilities to patients is always evolving